Clinical Trials on SCCHN

Total 31 results

Peking University
Biotech Pharmaceutical Co., Ltd.

Unknown

Safety and Efficacy Study of Target Therapy Combined With Radiotherapy to Treat Senile Locally Advanced SCCHN

SCCHN
NanoCarrier Co., Ltd.
Orient Europharma Co., Ltd.

Recruiting

Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen

SCCHN

Croatia, Czechia, Hungary, Poland, Russian Federation, Serbia, Taiwan, Ukraine
University Hospital, Caen

Unknown

Evaluation of the Overall Quality of Life After the Neck Dissection Retro-spinal Sector (IIb), in Squamous Cell Carcinomas Clinical and Radiological N0 VADS (QDV2b)

SCCHN

France
UNICANCER
Bristol-Myers Squibb

Completed

Nivolumab in Recurrent and/or Metastatic SCCHN (TopNIVO)

Recurrent and/or Metastatic Platinum-refractory SCCHN

France
AHS Cancer Control Alberta
Alberta Cancer Foundation

Unknown

Nivolumab Plus Pemetrexed for Head and Neck Squamous Cell Carcinoma (NivoPlus)

SCCHN

Canada
Stanford University
National Cancer Institute (NCI)

Completed

Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Squamous Neck Carcinoma of the Head and Neck Cancer (SCCHN)

United States
University of Alabama at Birmingham

Active, not recruiting

Chemo-embolization for Head and Neck Cancer

Squamous Cell Carcinoma | SCCHN

United States
Merck KGaA, Darmstadt, Germany
Merck Ltd., India

Terminated

A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (PMS LAD SCCHN)

Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck | LA SCCHN

India
Hoffmann-La Roche

Active, not recruiting

A Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)

United States, Korea, Republic of, Canada, Australia, Russian Federation, United Kingdom, Belgium, Brazil, China, France, Italy, Portugal, Spain, Japan, India, Thailand, Ukraine, Taiwan, Poland, Turkey, Hungary, South Africa, Germany
British Columbia Cancer Agency

Withdrawn

Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)

Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)

Canada
Massachusetts General Hospital
Dana-Farber Cancer Institute; Genentech, Inc.; Emory University; University of... and other collaborators

Terminated

Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck (SCCHN)

United States
Pfizer

Completed

Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer

Squamous Cell Carcinoma of the Head and Neck (SCCHN)

United States, Spain, Korea, Republic of, Czechia, Taiwan, Serbia, Japan, Slovakia, Mexico, Romania, Hungary, Italy, Poland, Russian Federation, Ukraine
Pfizer
EMD Serono; Astellas Pharma Inc; Nektar Therapeutics

Terminated

Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors

Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Metastatic Castration Resistant Prostate Cancer (mCRPC)

Spain, United States, Poland, Belgium
University of Michigan Rogel Cancer Center

Terminated

A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck

Squamous Cell Carcinoma of the Head and Neck (SCCHN)

United States
Dana-Farber Cancer Institute
Sanofi; Brigham and Women's Hospital

Completed

Study of Docetaxel in Combination With Cisplatin and 5-Fluorouracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of Head and Neck | Advanced Squamous Cell Carcinoma | SSCHN
Incyte Corporation

Active, not recruiting

Study of INCA 0186 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Gastrointestinal (GI) Malignancies

United States, Netherlands, Spain, United Kingdom, Belgium, Austria
Takeda

Recruiting

A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer

Colorectal Cancer | Non-small Cell Lung Cancer (NSCLC) | Squamous Cell Cancer of Head and Neck (SCCHN)

Korea, Republic of, United States, Australia
Eben Rosenthal
National Cancer Institute (NCI)

Completed

Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Head and Neck (SCCHN)

United States
AstraZeneca

Completed

Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer (EAGLE)

Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN

United States, France, Italy, Spain, Belgium, Czechia, Romania, Taiwan, Korea, Republic of, Brazil, Hungary, Japan, Russian Federation, Australia, Germany, Israel, Serbia, Bulgaria, Ukraine, Argentina, Poland, Chile, Croatia, Georgia
Novartis Pharmaceuticals

Terminated

Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy

Metastatic Colorectal Cancer | Squamous Cell Carcinoma of Head and Neck (SCCHN)

France, Belgium, Spain, Germany, Italy, Canada, United States
Pfizer

Completed

A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors

NSCLC | SCCHN | Part 1 | MELANOMA | OVCA | SARCOMA | OTHER SOLID TUMORS | Part 1 and 2 | UROTHELIAL CARCINOMA

United States, Korea, Republic of, Russian Federation, Poland, Malaysia, Bulgaria, Ukraine
Cascadian Therapeutics Inc.

Completed

Study of PX-866 and Docetaxel in Solid Tumors

Non Small Cell Lung Cancer (NSCLC) | Squamous Cell Carcinoma of the Head and Neck (SCCHN)

United States, Canada
Heidelberg University
University Hospital Heidelberg

Terminated

TPF Followed by Cetuximab and IMRT Plus Carbon Ion Boost for Locally Advanced Head and Neck Tumors (TPF-C-HIT)

Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN): Oro-, Hypopharyngeal and Laryngeal Cancer

Germany
Glenn J. Hanna
Secura Bio, Inc.

Active, not recruiting

Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC

Metastatic Head and Neck Cancer | Advanced Head and Neck Squamous Cell Carcinoma | Recurrent Squamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Advanced Head and Neck Cancer

United States
Celldex Therapeutics
Bristol-Myers Squibb

Completed

A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Ovarian Carcinoma-Enrollment Completed | Colorectal Cancer (CRC)-Enrollment Completed | Renal Cell Carcinoma (RCC) (Phase ll Only) | Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed

United States
Genmab
AbbVie

Terminated

A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors

Esophageal Cancer | Prostate Cancer | Bladder Cancer | Non-small Cell Lung Cancer (NSCLC) | Uterine Cancer | Triple Negative Breast Cancer (TNBC) | Squamous Cell Carcinoma of Head and Neck (SCCHN) | Locally Advanced or Metastatic Solid Tumor(s)

Spain, Israel, United States, Denmark
Exelixis

Recruiting

Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

Cervical Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Epithelial Ovarian Cancer | Metastatic Castration-resistant Prostate Cancer | Hormone Receptor-positive Breast Cancer | SCCHN | Esophageal SCC | Tissue Factor-Expressing Solid Tumors

United States, Spain, Australia, Belgium, France, Italy, Netherlands, United Kingdom, Korea, Republic of
Takeda

Recruiting

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Kidney Cancer | Breast Cancer | Nasopharyngeal Cancer | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Mesothelioma | Hepatocellular Cancer | Squamous Cell Cancer of Head and Neck (SCCHN) | Non-small Cell Lung Cancer (NSCLC), Non-squamous

United States
AHS Cancer Control Alberta
EMD Serono

Active, not recruiting

Avelumab With Valproic Acid in Virus-associated Cancer (LATENT)

Squamous Cell Carcinoma of the Cervix | Cancer That is Associated With a Chronic Viral Infection | p16 Positive SCCHN | p16 Positive Squamous Cell Carcinoma of the Vagina or Vulva | p16 Positive Squamous Cell Carcinoma of the Penis | p16 Positive Squamous Cell Carcinoma of the Anus or Anal... and other conditions

Canada
Seagen Inc.
Genmab

Completed

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Bladder Cancer | Cervix Cancer | Ovary Cancer | Esophagus Cancer | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Endometrium Cancer | Prostate Cancer (CRPC) | Lung Cancer(NSCLC)

United States, Belgium, United Kingdom, Denmark, Sweden
Incyte Biosciences International Sàrl

Completed

A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

Cervical Cancer | Hepatocellular Carcinoma | Esophageal Cancer | Ovarian Cancer | Mesothelioma | Non-small Cell Lung Cancer (NSCLC) | Urothelial Carcinoma | Merkel Cell Carcinoma | Diffuse Large B-cell Lymphoma | Triple-negative Breast Cancer | Renal Cell Carcinoma (RCC) | Small Cell Lung Cancer (SCLC) | Squamous... and other conditions

United States

Clinical Trials on SCCHN

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations